The discovery process in the pharmaceutical industry;Le processus de découverte du médicament dans lindustrie pharmaceutique

Journal de la Societe de Biologie

Volumn 203, Issue 3, 2009, Pages 249-269

  Scatton, Bernard ^a  

^a NONE   (France)

Author keywords

automated screening; biological targets; Drugs; phenotypic screening; research process

Indexed keywords

NEW DRUG;

ANIMAL; ANIMAL EXPERIMENT; BIOLOGICAL THERAPY; CELL CULTURE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; DRUG INDUSTRY; DRUG SCREENING; HUMAN; METHODOLOGY; MOLECULAR LIBRARY; RESEARCH; REVIEW;

ANIMAL EXPERIMENTATION; ANIMALS; BIOLOGICAL THERAPY; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH; SMALL MOLECULE LIBRARIES;

EID: 77951233207     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2009030     Document Type: Article

References (59)

1. Adams G.P., Weiner L.M., Monoclonal antibody therapy of cancer. Nat Biotechnol, 2005, 23, 1141-1157.
2. Anders H.J., Vielhauer V., Identifying and validating novel targets with in vivo disease models: Guidelines for study design. Drug Discov Today, 2007, 12, 446-451.
3. Andrews A.L., Holloway J.W., Holgate S.T., Davies D.E., IL-4 receptor α is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol, 2006, 176, 7456-7461.
4. Annis D.A., Nickbarg E., Yang X., Ziebell M.R., Whitehurst C.E., Affinity selection-mass spectrometry screening techniques for small molecule drug discovery. Curr Opin Chem Biol, 2007, 11, 518-526.
5. Austen M., Dohrmann C., Phenotype-first screening for the identification of novel drug targets. Drug Discov Today, 2005, 10, 275-282.
6. Borsook D., Becerra L., Hargreaves R., A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov, 2006, 1-14.
7. Boussery K., Belpaire F.M., Van de Voorde J., Physiological aspects determining the Pharmacokinetic properties of drugs. In The practice of Medicinal Chemistry, Wermuth C. (Ed.). Academic Press, 2008, pp. 637-654.
8. Brown D., Unfinished business: target-based drug discovery. Drug Discov Today, 2007, 12, 1007-101.
9. Butcher E.C., Can cell systems biology rescue drug discovery ? Nat Rev, 2005, 4, 461-467.
10. Butler D., Crossing the valley of death. Nature, 2008, 453, 840-842.
11. Carter P., Potent antibody therapeutics by design. Nat Rev Immunol, 2006, 6, 343-357.
12. Drews J., Ryser S., The role of innovation in drug development. Nat Biotechnol, 1997, 15, 1318-1319.
13. Frantz S., Playing dirty. Nature, 2005, 437, 942-943.
14. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F., Wadman W.J., Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci, 2006, 26, 11083-11110.
15. Halioua E., Evolution of biopharmaceutical and CMO market. IBC Biopharma contract manufacturing and partnering symposium, 2005.
16. Hardy J., Selkoe D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356.
17. Hartman I., Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res, 2008, 6, 54-67.
18. Hayden E.C., Personalized cancer therapy gets closer. Nature, 2009, 458, 131-132.
19. He X.P., Minichiello L., Klein R., McNamara J.O., Immunohistochemical evidence of seizure-induced activation of trkB receptors in the mossy fiber pathway of adult mouse hippocampus. J Neurosci, 2002, 22, 7502-7508.
20. He X.P., Kotloski R., Nef S., Luikart B., Parada L.F., McNamara J.O., Conditional deletion of trkB but not BDNF prevents epileptogenesis in the kindling model. Neuron, 2004, 43, 31-42.
21. Hillish A., Pineda L.F., Hilgenfeld R., Utility of homology models in the drug discovery process. Drug Discov Today, 2004, 9, 659-669.
22. Hoogenboom H.R., Selecting and screening recombinant antibody libraries. Nature Biotechnol, 2005, 23, 1105-1116.
23. Hopkins A., Groom C., The druggable genome. Nat Rev Drug Discov, 2002, 1, 727-730.
24. Imming P., Sinning C., Meyer A., Drugs, their targets and the nature and number of drug targets. Nature Rev, 2006, 5, 821-834.
25. Kola I., Landis J., Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Discov, 2004, 3, 711-715.
26. Kubinyi H., Drug research: myths, hype and reality. Nat Rev Drug Discov, 2003, 2, 665-668.
27. Kumar K.,Wetzel, S.,Waldmann H., Biology oriented synthesis and diversity oriented synthesis in compound collection development. In« The practice of Medicinal Chemistry»,Wermuth C. (Ed.). Academic Press, 2008, pp. 187-209.
28. Landry Y., Gies, J.P., Drugs and their molecular targets : an updated overview. Fundam Clin Pharmacol, 2008, 22, 1-18.
29. Langer T., Bryant S.D., In silico screening: hit finding from database mining. In« The practice of Medicinal Chemistry»,Wermuth C. (Ed.). Academic Press, 2008, pp. 210-227.
30. Levoye A., Jockers R., Alternative drug discovery approaches for orphan GPCRs. Drug Discov Today, 2008, 12, 52-58.
31. Lonberg N., Human antibodies from transgenic animals. Nat Biotechnol, 2005, 23, 1117-1125.
32. Macarron R., Critical review of the role of HTS in drug discovery. Drug Discov Today, 2006, 11, 277-279.
33. Morrissette D.A., Parachikova A., Green K.N., La Ferla, F.M., Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem, 2009, 284, 6033-6037.
34. Newman D.J., Craag G.M., Kingston D., Natural products as pharmaceuticals and sources for lead structures. In« The practice of Medicinal Chemistry», Wermuth C. (Ed.). Academic Press, 2008, pp. 159-186.
35. Nowicki J.P., Scatton B., Measurement and expression of drug effects. In« The practice of Medicinal Chemistry»,Wermuth C. (Ed.). Academic Press, 2008, pp. 73-84.
36. Owens J., 2006 drug approvals: finding the niche. Nat Rev, 2007, 6, 99-101.
37. Owens, D.R., Biol F.I., Bolli G.B., Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther, 2008, 10, 333-349.
38. Pangalos M.N., Schechter L.E., Hurko O., Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov, 2007, 6, 521-532.
39. Proudfoot J.R., High-throughput screening and drug discovery. In "The practice of Medicinal Chemistry", Wermuth C. (Ed.). Academic Press, 2008, pp. 144-158.
40. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C., Monoclonal antibody successes in the clinic. Nat Biotechnol, 2005, 23, 1073-1078.
41. Rondeau J.M., Schreuder H., Protein crystallography and drug discovery. In« The practice of Medicinal Chemistry»,Wermuth C. (Ed.). Academic Press, 2008, pp. 605-634.
42. Sams-Dodd F., Target-based drug discovery: is something wrong ? Drug Discov Today, 2005, 10, 139-147.
43. 3-adrenoceptor. Mol Pharmacol, 2008, 74, 1417-1428.
44. Scheffer I.E., Berkovic S.F., The genetics of human epilepsy. TIPS, 2003, 24, 428-433.
45. Schrama D., Reisfeld R.A., Becker J.C., Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov, 2006, 5, 147-159.
46. Serradeil-Le Gal, C., Wagnon J., Tonnerre B., Roux R., Garcia G., Griebel G., Aulombard A., An overview of SSR149415, a selective nonpeptide vasopressin V1b receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev, 2005, 11, 53-68.
47. Stasi R., Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther, 2008, 8, 527-540.
48. Steidl E.M., Neveu E., Bertrand D., Buisson B., The adult rat hippocampal slice revisited with multi-electrode arrays. Brain Res, 2006, 1096, 70-84.
49. Terstappen G.C., Schlüpen C., Raggiaschi R., Gaviraghi G., Target deconvolution strategies in drug discovery. Nat Rev, 2007, 6, 891-903.
50. Thakker D., Weatherspoon M., Harrison J., Keene T., Lane D., Kaemerrer W., Stewart G., Schafer L., Intracerebroventricular amyloid-β antibodies reduce cerebral amyloidangiopathy and associated microhemorrhages in aged Tg2576 mice. PNAS, 2009, 106, 4501-4506.
51. Tolner B., Smith L., Hillyer T., Bathia J., Beckett P., Robson L., Sharma S.K., Griffin N., Vervecken W., Contreras R., Pedley R.B., Begent R.H.J., Chester K.A., From laboratory to phase I/II cancer trials with recombinant biotherapeutics. Europ J Cancer, 2007, 43, 2515-2522.
52. Tsai S.J., TrkB partial agonists: Potential treatment strategy for epilepsy, mania and autism. Medical Hypotheses, 2006, 66, 173-175.
53. Venkateshan S.P., Sidhu S., Malhotra S., Pandhi P., Efficacy of biologicals in the treatment of rheumatoid arthritis. Pharmacology, 2009, 83, 1-9.
54. Wellendorph P., Goodman M., Burstein E.S., Nash N.R., Brann M.R., Weiner D.M., Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology, 2002, 42, 929-940.
55. Wermuth C.G., Strategies in the search for new lead compounds or original working hypotheses. In "The Practice of Medicinal chemistry", Wermuth C. (Ed.). Academic Press, 2008, pp. 125-143.
56. Wickenden A.D., Potassium channels as anti-epileptic drug targets. Neuropharmacology, 2002, 43, 1055-1060.
57. Wu A.M., Senter P.D., Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol, 2005, 23, 1137-1146.
58. Zavitz K.H., Bartel P.L., Hobden A.N., Drug targets, target identification, validation and screening. In« The Practice of Medicinal chemistry», Wermuth C. (Ed.). Academic Press, 2008, pp. 106-122.
59. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A., In vivo reprogramming of adult pancreatic exocrine cells to β cells. Nature, 2008, 455, 627-632.